Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones

May 07, 2025

DJ Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. $(INCY)$ shed 4.03% to $59.61 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.77% to 5,606.91 and Dow Jones Industrial Average falling 0.95% to 40,829.00.

This was the stock's second consecutive day of losses.

Incyte Corp. closed 28.99% short of its 52-week high of $83.95, which the company reached on November 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Alnylam Pharmaceuticals Inc. $(ALNY)$ fell 1.37% to $269.81, Bio-Techne Corp. $(TECH)$ fell 4.18% to $47.72, and BioMarin Pharmaceutical Inc. $(BMRN)$ fell 3.90% to $59.64.

Trading volume (2.3 M) eclipsed its 50-day average volume of 2.1 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 6, 2025.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

May 06, 2025 17:16 ET (21:16 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2533987856"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533987856\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533987856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533987856","market":"sh","top_or_hot":-1,"title":"Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nDJ Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors\n</p>\n<p>\n  This article was automatically generated by MarketWatch using technology from Automated Insights. \n</p>\n<p>\n     Shares of Incyte Corp. <a href=\"https://laohu8.com/S/INCY\">$(INCY)$</a> shed 4.03% to $59.61 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&amp;P 500 Index  falling 0.77% to 5,606.91 and Dow Jones Industrial Average  falling 0.95% to 40,829.00. \n</p>\n<p>\n     This was the stock's second consecutive day of losses. \n</p>\n<p>\n     Incyte Corp. closed 28.99% short of its 52-week high of $83.95, which the company reached on November 8th. \n</p>\n<p>\n     The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Alnylam Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/ALNY\">$(ALNY)$</a> fell 1.37% to $269.81, Bio-Techne Corp. <a href=\"https://laohu8.com/S/TECH\">$(TECH)$</a> fell 4.18% to $47.72, and BioMarin Pharmaceutical Inc. <a href=\"https://laohu8.com/S/BMRN\">$(BMRN)$</a> fell 3.90% to $59.64. \n</p>\n<p>\n     Trading volume (2.3 M) eclipsed its 50-day average volume of 2.1 M. \n</p>\n<p>\n     Data source: Dow Jones Market Data, FactSet. Data compiled May 6, 2025. \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2025 17:16 ET (21:16 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Corp. Stock Underperforms Tuesday When Compared To Competitors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-07 05:16</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nDJ Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors\n</p>\n<p>\n  This article was automatically generated by MarketWatch using technology from Automated Insights. \n</p>\n<p>\n     Shares of Incyte Corp. <a href=\"https://laohu8.com/S/INCY\">$(INCY)$</a> shed 4.03% to $59.61 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&amp;P 500 Index  falling 0.77% to 5,606.91 and Dow Jones Industrial Average  falling 0.95% to 40,829.00. \n</p>\n<p>\n     This was the stock's second consecutive day of losses. \n</p>\n<p>\n     Incyte Corp. closed 28.99% short of its 52-week high of $83.95, which the company reached on November 8th. \n</p>\n<p>\n     The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Alnylam Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/ALNY\">$(ALNY)$</a> fell 1.37% to $269.81, Bio-Techne Corp. <a href=\"https://laohu8.com/S/TECH\">$(TECH)$</a> fell 4.18% to $47.72, and BioMarin Pharmaceutical Inc. <a href=\"https://laohu8.com/S/BMRN\">$(BMRN)$</a> fell 3.90% to $59.64. \n</p>\n<p>\n     Trading volume (2.3 M) eclipsed its 50-day average volume of 2.1 M. \n</p>\n<p>\n     Data source: Dow Jones Market Data, FactSet. Data compiled May 6, 2025. \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2025 17:16 ET (21:16 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533987856","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533987856","pubTimestamp":1746566160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Incyte Corp.  shed 4.03% to $59.61 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.77% to 5,606.91 and Dow Jones Industrial Average  falling 0.95% to 40,829.00.This was the stock's second consecutive day of losses.Incyte Corp. closed 28.99% short of its 52-week high of $83.95, which the company reached on November 8th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Alnylam Pharmaceuticals Inc.  fell 1.37% to $269.81, Bio-Techne Corp.  fell 4.18% to $47.72, and BioMarin Pharmaceutical Inc.  fell 3.90% to $59.64.Trading volume  eclipsed its 50-day average volume of 2.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled May 6, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Do","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗"},"translate_title":"与竞争对手相比，Incyte Corp.股票周二表现不佳","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1},"content_text":"DJ Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors\n\n\n  This article was automatically generated by MarketWatch using technology from Automated Insights. \n\n\n     Shares of Incyte Corp. $(INCY)$ shed 4.03% to $59.61 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.77% to 5,606.91 and Dow Jones Industrial Average  falling 0.95% to 40,829.00. \n\n\n     This was the stock's second consecutive day of losses. \n\n\n     Incyte Corp. closed 28.99% short of its 52-week high of $83.95, which the company reached on November 8th. \n\n\n     The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Alnylam Pharmaceuticals Inc. $(ALNY)$ fell 1.37% to $269.81, Bio-Techne Corp. $(TECH)$ fell 4.18% to $47.72, and BioMarin Pharmaceutical Inc. $(BMRN)$ fell 3.90% to $59.64. \n\n\n     Trading volume (2.3 M) eclipsed its 50-day average volume of 2.1 M. \n\n\n     Data source: Dow Jones Market Data, FactSet. Data compiled May 6, 2025. \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2025 17:16 ET (21:16 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}